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Abstract 
A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium 
perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard 
therapy received weekly APFO doses (50mg-1200mg) for six-weeks. Clinical chemistries and 
plasma PFOA (anionic APFO) were measured pre-dose and weekly thereafter. Several clinical 
measures including total cholesterol, high-density lipoproteins (HDL), thyroid stimulating 
hormone (TSH), and free thyroxine (fT4), relative to PFOA concentrations, were examined by: 
standard statistical analyses using general estimating equations (GEE) and a probabilistic 
analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 
two-compartment pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean 
changes. Based on the GEE, the average rates of change in total cholesterol and fT4 associated 
with increasing PFOA were approximately -1.2x10-3mmol/L/µM and 2.8x10-3pmol/L/µM,
respectively. The PK/PD model predicted more closely the trends observed in the data as well as 
the pdfs of biomarkers. A decline in total cholesterol was observed, with a clear transition in 
shape and range of the pdfs, manifested by the maximum value of the Kullback-Leibler  (KL) 
divergence, that occurred at plasma PFOA between 420 and 565 µM (175,000–230,000 ng/mL).  
HDL was unchanged.  An increase in fT4 was observed at a higher PFOA transition point, albeit 
TSH was unchanged.   Our findings are consistent with some animal models and may motivate 
re-examination of the epidemiological studies to PFOA at levels several orders of magnitude 
lower than this study. These observational studies have reported contrary associations, but 
currently understood biology does not support the existence of such conflicting effects. 
Keywords: APFO; cholesterol; PFOA; phase 1 trial; PK/PD modeling; thyroid. 
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Introduction 
The ammonium salt of perfluorooctanoate (APFO, NH4
+ C7F15COO
-) was used for decades in 
industrial applications as an emulsifier in fluoropolymer manufacturing, including the 
polymerization of tetrafluoroethylene (PTFE) (Buck et al., 2011). Due to environmental and 
toxicological concerns, the industrial use of APFO has been phased-out in the United States (US 
EPA 2006). 
APFO is absorbed orally, (Kennedy et al., 2004), readily dissociates to perfluorooctanoate 
(herein also referred to as PFOA) in the blood, and binds to serum protein. PFOA does not 
metabolize and is excreted in urine and feces. Urinary elimination rates vary among the 
perfluorocarboxylate homologues and renal tubular secretion and reabsorption depends on sex, 
species, and chain-length. For PFOA, serum elimination half-life values range from hours/days 
(rats), weeks (mice), or months (monkeys) (Butenhoff et al., 2004; Han et al., 2012; Lou et al., 
2009), whereas in humans it ranges between 2.3 to 3.5 years (Bartell et al., 2010; Olsen et al., 
2007a; Russell et al., 2015).  Serum PFOA concentrations have declined in the United States 
general population between 2000 - 2015 (Olsen et al. 2017). 
While APFO is not genotoxic (Butenhoff et al., 2014), chronic bioassays in Sprague Dawley rats 
with dietary administration of APFO (up to 300 ppm) resulted in hepatic and pancreatic acinar 
cell adenomas (Biegel et al., 2001) or a proliferative response in the acinar pancreas (Butenhoff 
et al., 2012a; Caverly Rae et al., 2014). Both studies also reported an increase in Leydig cell 
adenomas. Various levels of confidence regarding the mode of action for these three tumors have 
been attributed to activation of the xenosensor nuclear receptor peroxisome proliferator-activated 
receptor α (PPARα) (Klaunig et al., 2012). Weight of evidence indicates that the mode of action 
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steps for liver tumors is not likely relevant to humans (Gonzalez et al., 1998; Rosen et al., 2009; 
US EPA, 2003); whereas a similar PPARα-mediated mode of action was considered plausible for 
pancreatic tumors (Klaunig et al., 2012). While the prevalence of Leydig cells tumors is low in 
humans (0.00004 %) compared to the occurrence in Sprague Dawley rats (5.3 %) (Cook et al., 
1999), the increased incidence of such tumor type in rats with exposure to APFO and its 
relevance to humans remains recondite.  
Occupational epidemiology studies have reported inconsistent associations between PFOA and 
kidney cancer that may have been confounded by other workplace exposures (Consonni et al., 
2013; Raleigh et al., 2014; Steenland et al. 2012). A study of a mid-Ohio river valley community 
and worker population (n = 32,254), exposed to drinking water containing PFOA from an 
industrial source, reported a significant trend for testicular cancer (17 cases) with a 
nonsignificant trend observed for kidney cancer (105 cases) (Barry et al., 2013). The 
International Agency for Research on Cancer (IARC) categorized PFOA as a possible human 
carcinogen for testicular and kidney cancer (Group 2B) (Benbrahim-Tallaa et al., 2014).  
In light of this IARC qualitative hazard index listing and the presence of PFOA in the general 
population, it is highly unusual that an environmental toxicant such as PFOA would ever be 
considered for its chemotherapeutic properties. Interestingly, PFOA has been shown to cause 
endoplasmic reticulum stress in tumor cells, activity against PIM kinases, and activity in five 
xenograft models of solid tumors (Barnett et al., 2010). Because PIM kinases can be 
overexpressed in many cancers that involve cell survival, cell cycle progression, and cell 
migration, inhibitors of PIM kinases have become a focus for drug discovery research, including 
APFO (Blanco-Aparicio and Carnero, 2013). Based on APFO’s antitumorgenicity profile, a 
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phase 1 trial was sponsored by CXR Biosciences, Ltd. (2 James Lindsay Pl, Dundee DD1 5JJ, 
UK) to determine the safety, dose-limiting toxicity, and maximum tolerated dose of APFO.  
This phase 1 trial also enabled detailed evaluation of various clinical chemistries. Observational 
epidemiologic research has reported positive associations between measured or modeled serum 
PFOA concentrations and higher serum cholesterol (Nelson et al., 2010; Steenland et al., 2009;  
Winquist and Steenland 2014a). These findings, however, are contrary to the PPARα-mediated 
lowering of serum lipids that occur in rodents treated with APFO (Kennedy et al., 2004) as well 
as the pharmacodynamic reduction of serum lipids in humans mediated by the PPARα agonist 
fibrate drugs (Roy and Pahan, 2009).  
The purpose of this paper is to describe this APFO phase 1 trial and the time-dependent 
relationships that were observed over the course of this study between administered doses of 
APFO, plasma concentrations of PFOA, and several clinical markers, including cholesterol, in 
the participating subjects. 
 Methods 
2.1 Study design for phase 1 trial of APFO 
This open-label, non-randomized, phase 1 study used a dose escalation design (Le Tourneau et 
al., 2009).  The study was conducted in 2008 - 2011 at two centers in Scotland: Beatson West of 
Scotland Cancer Centre (Glasgow) and the Aberdeen Royal Infirmary. CXR Biosciences 
(Dundee, Scotland) was the study sponsor. The study was conducted in accordance with the 
International Conference on Harmonization of Good Clinical Practice and approved by the 
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Glasgow West Research Ethics Committee. All subjects provided written informed consent prior 
to undergoing any study-related procedure.   
 
2.1.1 Subject eligibility 
Patients with histologically or cytologically confirmed advanced solid tumors, refractory to 
standard anti-cancer therapy or for which no standard therapy existed, were recruited in this 
study. Other inclusion criteria for study subjects were: >18 years, physician-assessed life 
expectancy greater than three months, adequate hematological function, able to comply with 
study procedures, and written consent. Exclusion criteria included any anti-cancer therapy within 
the last four weeks (including chemotherapy, radiotherapy, endocrine therapy, immunotherapy, 
or use of other investigational agents), HIV infection, hepatitis B or hepatitis C positivity, 
inadequate renal function, abnormal liver function tests, lack of physical integrity of the GI tract 
that might lead to impaired administration and absorption of the oral therapy, and uncontrolled 
cardiac disease. APFO is a potent inhibitor of CYP2C (Elcombe et al., 2011); therefore, patients 
taking warfarin, phenytoin, or tolbutamide were excluded from the trial.  
2.1.2 Pre-treatment evaluation 
For each subject, pretreatment evaluations included a full medical history, tumor evaluation, 
chest X-ray and 12-lead ECG, full blood count and coagulation screen, biochemical profile 
including urea, electrolytes, alanine transaminase (ALT), aspartate transaminase (AST), alkaline 
phosphatase, bilirubin, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein 
Downloaded from https://academic.oup.com/toxsci/advance-article-abstract/doi/10.1093/toxsci/kfy035/4865972
by Library - Duncan of Jordanstone user
on 08 March 2018
Page 8 
 
(HDL), triglycerides, albumin, calcium, urea, uric acid, thyroid stimulating hormone (TSH), free 
thyroid hormone (fT4), blood glucose, urinalysis, and a physical examination.  
2.1.3 Trial treatment 
Based on known APFO pharmacokinetics in monkeys (Butenhoff et al. 2004), treatment could 
be administered orally via gelatin capsules that would result in the desired plasma PFOA 
concentrations. Therefore, the study drug was administered in powder-filled hard gelatin 
capsules containing 50 mg of APFO. The bulk active pharmaceutical ingredient was 
manufactured under Good Manufacturing Practices conditions by Chimete Srl ( Tortona, Italy). 
The capsules were manufactured according to GMP by Penn Pharmaceutical Services, LTD 
(Tredegar, UK). 
The pharmacy at each institution controlled the dispensing of APFO. The administration of 
APFO to the subject occured by authorized staff to ensure treatment compliance. Prophylactic 
anti-emetics were not administered, and subjects were requested to fast for one hour after 
ingestion of APFO. If a subject vomited after ingestion of the oral capsule, then the time of the 
event was recorded but another capsule was not administered to replace this administration of 
APFO. Blood samples for pharmacokinetic (PK) analysis as well as for clinical chemistries were 
taken over the following six-week period. Following this 6-week trial period, the subjects could 
continue treatment with weekly administration of drug should they so desire in consultation with 
their physician. For the purpose of this paper, analyses focus on the six-week trial period. 
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2.1.4.Treatment cohorts 
2.1.4.1 Initial dose cohort 
APFO was administred orally as a single dose of 50 mg in the morning after an overnight fast in 
the first cohort of three subjects and pharmacokinetic and pharmacodynamic (PK/PD) 
parameters were measured over a six-week period. No further dosing was given to this cohort 
during the six-week period. 
2.1.4.2 Dose escalation cohorts 
In a 3+3 dose escalation trial design for a phase 1 clinical trial (Le Tourneau, 2009), three 
subjects are enrolled into a given dose cohort.  If there is no dose limiting toxicity (DLT) 
observed among these subjects, the trial proceeds to enroll additional subjects into the next 
higher dose cohort. If  DLT occurrs in 1 of 3 subjects within an individual dose cohort, then up 
to three more subjects can be treated at this dose level and dose escalation is only allowed if no 
further DLT is observed. If DLT occurrs in 2 of 3 subjects within an individual dose cohort, then 
no further dose escalation is allowed. The dose level immediately below the maximum 
administered dose is then defined as the maximum tolerated dose (MTD). An additonal cohort of 
subjects could be treated at this MTD up to a total of 12 subjects. 
In the dose cohorts that followed the inital dose cohort, subjects were treated with weekly 
administration of APFO from the start of dosing. Dose escalation was performed only after the 
subjects at the preceding dose level had completed a 3-week repeat dosing period. If a subject 
had not completed three weeks of repeat dosing with APFO for reasons other than toxicity (e.g., 
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withdrawal of consent), the subject was replaced for the purpose of toxicity evaluation. All 
subjects who were dosed were included in this analysis of the data. 
In the present study, the dose of APFO was initially doubled in successive cohorts until a  ≥ 
Grade 2 drug-related toxicity was observed. The dose assigned to a specific dose cohort was 
reviewed and determined by the investigators and study sponsor before any subjects were treated 
at a new dose level. No intra-subject dose escalation was allowed.  
Subjects were allowed to receive supportive care therapies. All medications (prescription and 
over-the-counter) taken during the course of the trial were documented. No other chemotherapy, 
immunotherapy, hormonal therapy, radiation therapy, or other experimental therapies were 
permitted during the trial. However, a subject’s clinical needs were paramount, and if a restricted 
concomitant medication or therapy was required while the subject was enrolled in the trial then 
this may have necessitated withdrawal of the subject. 
2.1.5 Treatment discontinuation 
Treatment discontinuation was considered in the event of a subject decision to withdraw consent 
to further treatment, treatment-related serious adverse events, recurrent DLT despite appropriate 
dose-modifications, progression of the underlying malignant disease, and if further treatment 
with APFO was contra-indicated in the opinion of the investigator. 
2.1.6 Pharmacokinetic assessment 
For the inital dose cohort, who received a single dose (50 mg) of APFO, PFOA in plasma was 
measured at pre-dose, and then 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 24, 48, and 72 hours after 
administration and then once weekly at weeks 2 through 6. For those subjects with repeat dose-
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administration, blood samples were taken at pre-dose and then 2, 3, 4, and 24 hours after each 
weekly administration for 6 weeks. A complete pharmacokinetic assessment is reported 
elsewhere (Campbell et al., manuscript in preparation). 
2.1.7 Analytical measurement of PFOA 
Details are presented in the Supplemental Material.  All analytical measurements of PFOA were 
conducted by CXR Biosciences (Dundee, Scotland). Plasma PFOA was reported in µM (µM 
PFOA = 413 ng/mL).  The method used 40 µL plasma, solvent extraction followed by 
LC/MS/MS, and provided sufficient detectability (i.e. lower limit of quantitation (LLOQ) of 5 
ng/mL) to fully define the pharmacokinetics following the initial dose. This LLOQ is 
inappropriate for the levels found in general human populations. However, calibration and 
quality control standards were adjusted as appropriate to cover the range required with increasing 
dose.  Accuracy was within 15% of the actual value and precision did not exceed 15% of the 
coefficient of variation (CV) at all concentrations above the LLOQ.  The LLOQ was established 
as the lowest point on the calibration with accuracy and precision within 20% limits.   
2.1.8 Pharmacodynamic assessment 
For those subjects with repeat dose-administration, blood samples for clinical measures were 
taken after an overnight fast: pre-dose, 2 and 24 hrs post-dose for 6 weeks and analyzed in the 
hospital clinical laboratories. Units of reported measurement were the following: serum lipids: 
total cholesterol, LDL, and HDL (mmol/L = 38.6 x mg/dL); serum triglycerides:  (mmol/L = 
88.5 x mg/dL); thyroid: TSH (mIU/L) and fT4 (pmol/L = 0.08 x ng/dL); glucose: (mmol/L = 18 
x mg/dL); liver and pancreatic enzymes and bilirubin: ALT, AST, gamma glutamyl transaminase 
(GGT), alkaline phosphatase, amylase (IU/L), and total bilirubin (mg/L); liver function blood 
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clotting tests: fibrinogen (g/L), prothrombin time (PTT) (s), activated partial thromboplastin time 
(aPTT) (s); serum proteins: total, albumin, and globulin (mg/dL); and renal clinical chemistries: 
serum creatinine (µmol/L = 0.0113 x mg/dL); urea: (mmol/L = BUN (mg/dL) x 0.3571); and uric 
acid: (µmol/L = 0.0168 x mg/dL).  
2.1.9 Tumor response 
Tumor response was assessed clinically every three weeks and involved radiological evaluation 
of disease at the end of the six-weeks,  as well as for those who requested continued treatment.  
Response to APFO treatments was recorded using the RECIST criteria (Therasse et al., 2000) in 
subjects with measureable disease. These tumor response findings are not reported herein. 
2.2 Statistical Analyses 
Internal dosimetry of PFOA, not the dose group, was considered the most appropriate metric for 
the evaluation of the clinical chemistries. The baseline (before first dose) and subsequent 24-hour 
post-dose plasma PFOA and clinical chemistry results (through the six treatments) were 
considered for statistical analyses and characterized by estimating the univariate and bivariate 
distributions, and examining for outliers and other anomalies. Simple graphic displays were used 
to characterize these distributions, including box plots and scatter plots. Autocorrelations and 
intra-class correlations (ICC) of the time series were estimated and Box-Cox transformations to 
normalize raw data were evaluated. To accommodate correlation of values within subject, 
generalized estimating equation (GEE) models were fitted to estimate the trends in clinical 
chemistries over concentrations of PFOA. 
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2.3 Combining Toxicological and Epidemiological Information via an Information 
Theoretic PK/PD Model  
In order to replicate the observed PK/PD, we tested different metamodels (i.e., different models 
with different parameters or values of parameters) for which the goal was to reproduce selected 
observed patterns with the highest accuracy. These patterns were (1) the variation of PFOA over 
time; (2) the probability distribution functions (pdf) of PFOA and clinical chemistries over time; 
and (3) the patterns of clinical chemistries (e.g., total cholesterol, HDL, triglycerides, TSH, and 
fT4) conditional on different levels of PFOA. Note that these three patterns encompass the 
classical PK and PD relationships, better defined as the concentration-time, effect-time, and 
effect-concentration relationships, respectively. The model architecture used for the PK/PD 
modeling was the one proposed by Lindhardt and Gennemark (2014). This model has been 
implemented in the ‘‘PopED lite’’ computational platform 
(http://www.bluetree.me/PopED_lite.html). PopED lite is a computational technology for clinical 
pharmacokinetic and pharmacodynamic studies (software and documentation is found at 
http://arxiv.org/abs/1505.06658v1). PopED lite focuses on optimization of the dosage and 
PK/PD sampling (or observation) times to improve the accuracy of the parameter estimates of 
fixed-effect PK/PD models. Thus, model design (‘metamodeling’) (Saltelli et al., 2004) via 
global sensitivity and uncertainty analyses (GSUA) in this context refers to the selection of the 
optimal probability distribution functions and value ranges that maximize the accuracy of 
predicting the three patterns considered. Prediction accuracy is assessed by three accuracy 
indicators: the root mean square error (RMSE), the Kullback-Leibler divergence over time (KL), 
and the Akaike Information Criterion (AIC). These three indicators are deterministic, 
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probabilistic and model validation criteria, respectively, and are calculated for all three patterns 
considered. RMSE is a classical indicator of model performance that depends on average values 
of variables; KL is a probabilistic indicator that considers the whole probability distribution of 
variables; and AIC is a computational complexity indicator that considers the number of 
parameters in the model. The selection of these evaluation indicators allowed for global 
assessment of model performance and determination of its reliability. One advantage was 
examination of the sensitivity of the estimated effect of interest to the distributions underlying 
the other parameters in the model. From this there can be an assessment to what extent the 
findings can be influenced by the model form and parameterization. For a more complete 
development of the GSUA model and pertinent implementation details, see Supplementary 
Information. 
The PK of the population cohort was modeled by a linear two-compartment model as 
 
 
where Cpu and C2 represent unbound concentration in the plasma compartment and in a second 
tissue compartment, respectively. D is the weekly dose given (zero for the baseline value) and 
the parameters V (volume of distribution), ka, k12, k21, and k10 are calibrated simultaneously in a 
fitted model that considers the data and aims to maximize multi-pattern prediction accuracy (see 
Supplementary Information for details). The PD of the population cohort of the drug was 
modeled as follows. A first-order distribution delay of compound to and from the biophase 
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(compartment) was assumed to be the rate-limiting step, and thus requires no assumptions about 
the timing of response, and an effect-compartment model was used, where the concentration in 
the effect compartment was linked to the plasma compartment by a first-order equilibrium rate 
constant ke. The rate of change of compound concentration in the effect compartment could then 
be expressed by 
 
 
where C′eu denotes the unbound effect compartment concentration. The observed PD effect was 
modeled by a power function as  
 
 
where E denotes the effect variable (such as total cholesterol and fT4 but in general could be any 
clinical chemistry), and a and b are calibrated input factors whose specific value depends on the 
effect compartment but whose probability distribution does not (see Supplementary Information 
for details). In this way, we keep the power exponent b and the scaling factor a as effect-
dependent factors but the structure of the observed PD effect is invariant, as should be expected. 
The effect compartment represents the target site concentration, and is used to infer 
concentration-effect relationships (or PD relationships versus the concentration-time PK 
relationships) without ambiguity from variability of delays in effect. The model was calibrated 
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for one week and validated for the next five weeks of the six-week phase 1 trial in which the 
population cohort was studied.  
A sensitivity analysis was conducted to determine the influence of the study subjects’ treatment 
with cholesterol lowering drugs, thyroid medications, and corticosteroids. 
 3 Results  
3.1 Systemic Response  
A total of 50 subjects (22 female, 28 male) were initially enrolled and 49 underwent the 
treatment in this phase 1 trial of APFO. (See Table 1.) These 49 subjects were on average 61 
years of age, were 1.7 m in height, and weighed 75 kg (Table S1). Estimates of autocorrelation 
and ICC were small enough to ignore, thus for the purposes of modeling, all measurements were 
treated as independent. Table S2 provides the distribution of tumor sites and a breakdown of the 
colorectal and pancreatic cancers by stage.  
No more than one subject showed DLT at any dose so therefore the protocol-defined MTD was 
not reached.  The recommended phase 2 dose (RP2D) of 1,000 mg weekly was based on 
tolerability of common cumulative drug-related toxicities which consisted primarily of fatigue, 
nausea, vomiting, and diarrhea. Stable disease for > 12 weeks was observed in 8 subjects 
including subjects with anaplastic thyroid (40 weeks), pancreatic (35 weeks) and colon (34 
weeks) cancer (MacPherson et al., 2011).  
3.2 Plasma PFOA concentrations 
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The trajectory of both observed and modeled plasma concentrations of PFOA over time for 
different dose groups are provided in Figure 2. The plot shows that, although cumulative dose 
goes up linearly, plasma concentration begins to plateau with increasing dose categories. The 
highest dose category showed a plateau at around 600 hours into the dosing period. 
3.3 PK/PD Modeling 
The two clinical chemistry measures that showed clearly observable associations with PFOA 
concentrations were total cholesterol and fT4. 
Based on the GEE analysis for total cholesterol (Figure 3), the average rate of change in total 
cholesterol with increased PFOA concentration was approximately -1.2 x 10-3 mmol/L/µM 
(Figure 3).   
There was a clear transition in shape and range of the pdf for a decrease in total cholesterol 
(Figures 4 and 5) that occurred at roughly PFOA levels between 420 and 565 µM (approximately 
175,000–230,000 ng/mL).  This transition is manifested by the maximum value of the KL 
divergence quantified between pdfs of all PFOA categories. These PFOA concentrations are 
several orders of magnitude higher than reported in workers or the general population.  Figure 6 
displays pdf results for total cholesterol, HDL, and LDL demonstrating that the impact of PFOA 
was on decreased LDL but  not  HDL. In addition, the variability of total cholesterol was higher 
at lower PFOA levels. The higher dosed subjects experienced a relatively narrower range of total 
cholesterol values but much higher variability in PFOA plasma concentration.  Supplementary 
Information Figure S1 demonstrates the same results for subjects grouped in three different 
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treatment bins used to calculate the average value of total cholesterol, verifying the robustness of 
these analyses.   
Based on the GEE analysis for fT4 (Figure 7), the average rate of change in fT4 was 2.8 x 10-3 
pmol/L/µM with a transition in shape and range of the pdf at higher concentrations of PFOA 
(Figure 8) than seen with cholesterol. This transition is manifested by the maximum value of the 
KL divergence quantified between pdfs of all PFOA categories. In Figure 9, which graphs both 
TSH and fT4 pdf as a function of PFOA plasma concentration, it is clear that only fT4 was 
influenced (increased) by PFOA, not TSH. Compared to cholesterol, the distribution of fT4 
appeared not to narrow with increasing PFOA level. Figure S1 also presents the fT4 results with 
subjects grouped by the three treatment bins. 
Based on the analysis of the PK/PD model, the average rate of decrease in total cholesterol and 
increase of free T4 associated with increasing PFOA were approximately -0.30 x 10-2 
mmol/L/uM and 2.66 x 10-3 pmol/L/uM, respectively; thus, the GEE underestimates the change 
of cholesterol, but predicts relatively correctly the change in fT4. Note that the change in fT4 
was not as non-linear as the change in cholesterol considering the pdfs of these biomarkers. 
Despite the largest change is observed for cholesterol (probabilistically speaking), the change in 
the average value (explained linearly) is small, and smaller than the average change of fT4, 
despite the latter is changing less than cholesterol probabilistically. This is clearly related to the 
non-linear dynamics where seemingly small changes in average values actually produce large 
effects.   
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Figures 10 and 11 present pdfs for ALT and serum creatinine, respectively, by plasma PFOA 
group. Both clinical chemistries did not show appreciable changes as a function of PFOA levels. 
It is possible that serum creatinine was higher for a few individuals for highest values of PFOA, 
but there is little evidence of any impact on ALT.  
The dynamics of other clinical measures — triglycerides, urea, glucose, AST, GGT, alkaline 
phosphatase, total bilirubin, fibrinogen, PTT, and aPTT — show almost no observable 
differences with measured plasma PFOA concentrations. (Figures S2 - S6). 
Sensitivity analyses displays the results for cholesterol and fT4 robust to subject treatment with 
statins (n = 6 subjects), thyroxine (n = 3 subjects), and corticosteroids (18 subjects). 
(Supplementary Information Figures S7 - S10). 
The most important result of GSUA performed for the stochastic PK/PD model showed the 
relative importance between compartment effects factors and dose-plasma factors (Figures S11 
to S13). Details of these analyses are given in the Supplementary Information. Viewed from the 
perspective of the plasma concentration, the factor D is the most important driver of the whole 
model. The second most important factors are a, b, and ke, which determine the PD response, our 
main interest here. For each of these factors, the dependence on other factors is balanced by their 
independent impact. Although somewhat dependent on other factors, these estimates are 
generally robust. Non-negligible, particularly in terms of model factor interactions, are the 
plasma-compartment factors k12, k21, and k10. In other words, the way in which the drug is 
assimilated by each model compartment is important to the concentration. The volume V and the 
absorption rate ka did not seem to determine significantly the PK/PD dynamics.  
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4. Discussion 
4.1 PFOA and Lipid Dynamics  
The plasma PFOA concentrations measured in this phase 1 study are the highest ever reported in 
humans. At plasma PFOA concentrations between 420 and 565 µM (approximately 175,000 – 
230,000 ng/mL), there was a marked decrease in serum total cholesterol but not in HDL. This 
reduction in non-HDL cholesterol is consistent with the known pharmacodynamics of PPARα 
agonists used to treat hyperlipidemia in humans. For example, the fibrate drugs (e.g., clofibrate), 
work through the regulation of genes involved in lipid metabolism (Roy and Pahan, 2009). 
PFOA activates human PPARα both in vitro in primary hepatocytes (Bjork and Wallace, 2009) 
and in vivo in humanized PPARα mice (Albrecht et al., 2013).  
The phase 1 results are generally consistent with the toxicological evidence, where PFOA has 
been shown to activate PPARα and regulate the transcription of genes involved with lipid 
metabolism in rats and mice (Albrecht et al., 2013; Elcombe et al., 2010). Rodents treated with 
APFO over 14 days showed decreased serum lipids at PFOA levels between 20,000 – 51,000 
ng/mL in rats and 10,000 – 14,000 ng/mL in mice (Loveless et al., 2006). A study of C57BL/6 
and BALB/c mice fed a high cholesterol and fat diet containing PFOA, found elevated 
hypercholesterolemia (primarily HDL) (Rebholz et al. 2016) but this was not supported by a 
study of humanized ApoE*3.Leiden.CETP mice (Westerterp et al. 2006), in which a Western 
diet containing APFO resulted in decreased plasma non-HDL cholesterol and triglycerides 
(Princen et al. 2016). Hypolipidemia was not observed in cynomolgus monkeys with repeated 
oral administration of APFO over six months (Butenhoff et al., 2002).  Human PPARα receptors 
have comparable affinity to PPARα agonists (Corton et al., 2014), but less than 10% the level of 
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PPARα receptors compared to rats and mice (Gonzalez et al., 1998).  It is, therefore, reasonable 
to conclude that the hypolipidemic response observed in the phase 1 trial subjects may be 
consistent with a PPARα-mediated mode of action. 
Several observational epidemiological cross-sectional studies of general populations have 
reported positive associations between serum cholesterol (primarily LDL) and PFOA (Eriksen et 
al., 2013; Geiger et al., 2014; Nelson et al., 2010; Starling et al., 2014) at approximately 4 orders 
of magnitude lower concentrations than in this phase 1 study.  Furthermore, the modest 
association observed in studies of general populations is inconsistent with the weaker 
associations reported in more highly exposed workers (Costa et al. 2009; Olsen and Zobel, 2007; 
Sakr et al., 2007a; 2007b; Steenland et al. 2010a; 2015).  An association between high 
cholesterol and measured PFOA (Fitz-Simon et al., 2013; Frisbee et al., 2010; Steenland et al., 
2009) and model-derived cumulative PFOA (Winquist and Steenland 2014a) has been reported 
in a mid-Ohio river valley community whose drinking water contained PFOA from a nearby 
fluoropolymer plant.  However, there was no increased risk for coronary artery disease related to 
PFOA exposure in this population.  The C8 Science Panel (2012a) considered the observed 
increased risk for high cholesterol with exposure to PFOA small in magnitude and would 
therefore not necessarily result in increased heart disease given its other attributable risk factors.  
Studies of highly exposed PFOA occupational cohorts have also not reported increased risks 
with either coronary artery disease incidence (Steenland et al., 2015) or mortality (Raleigh et al., 
2014; Steenland and Woskie, 2012) when using internal referent comparisons to minimize 
confounding by non-representative general referent populations. 
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Because of the consistency from this phase 1 trial and toxicological studies demonstrating lower 
cholesterol with high concentrations of PFOA, on the one hand, and the inconsistency with the 
observational epidemiologic associations showing higher cholesterol with markedly lower PFOA 
concentrations on the other, future research should address non-causal biological explanations 
for the latter. Several possibilities include: 
 1) Inherent variability in the glomerular filtration rate (GFR), which confounds other 
associations reported with PFOA, including lower birthweight (Verner et al., 2015) and chronic 
kidney disease (Watkins et al., 2013). Studies have shown that individuals with dyslipidemia, as 
well as those taking a much less aggressive atorvastatin treatment for their dyslipidemia, have 
lower GFR (Lin et al., 2015; Shepherd et al., 2007).   These studies may suggest that elevated 
cholesterol may affect GFR which may then result in increased retention of PFOA. 
2) Organic anion transporters in the gastrointestinal tract and liver that may share binding affinity 
with lipids and PFOA, analogous to the URATE transporter in the proximal tubule and uric acid 
and PFOA (Han et al., 2012). Organic anion transporting polypeptides in human and rodent 
hepatocytes and enterocytes have been shown to transport PFOA, thus contributing to its 
enterohepatic circulation (Zhao et al., 2017). Thus, persons with increased enterohepatic 
circulation transport of lipids may also have increased retention of PFOA. 
3) Saturation in an underlying physiologic mechanism given the nonlinear association between 
PFOA and cholesterol, as was suggested by Steenland et al. (2009) and Frisbee et al. (2010).  
This could involve reabsorption at the proximal tubule and/or enterohepatic reuptake. 
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4) Lipoproteins that may bind with PFOA, but this is less plausible since 99% of the PFOA in 
one human donor sample was distributed in lipoprotein-depleted plasma (Butenhoff et al., 
2012b). Additional study subjects would be reassuring to assess this result. 
Plausible biological modes of action that support the hypercholesterolemia positive association 
reported at low ng/mL PFOA concentrations, while explaining negative association at high 
concentrations, also need to be investigated. Serum PFOA concentrations as low as 50 ng/mL 
have not resulted in higher cholesterol levels in humanized ApoE*3.Leiden.CETP mice given the 
reduction in cholesterol at higher PFOA concentrations (personal communication H Princen, 
TNO Biosciences). Therefore, there needs to be a concerted effort to focus on modes of action to 
address the existence of a PFOA-mediated effect with the positive cholesterol associations 
reported in observational epidemiologic studies.    
4.2 PFOA and Thyroid Function 
The observable increase in fT4 seen in this phase 1 trial, with no apparent effect on TSH, 
suggested that the increase in fT4 was not clinically significant but may be due to displacement 
of thyroid bound hormone by PFOA. These findings appear similar to the toxicological evidence 
in laboratory studies with perfluorooctanesulfonate (PFOS), which displaced thyroxine from 
binding proteins in rats, transiently increasing free thyroxine without altering overall thyroid 
hormone homeostasis (Chang et al., 2007; 2008 Weiss et al. 2009). PFOA is structurally similar 
to PFOS in that both compounds resemble a fatty acid in their amphiphilic nature and compete 
for binding with free fatty acids on albumin and liver fatty-acid binding protein (Luebker et al., 
2002), and therefore, PFOA can also similarly displace thyroxine (Butenhoff et al. 2012c). Such 
displacement has been shown with aspirin, heparin, and free fatty acids (Koulouri et al., 2013).   
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Analogous to the cholesterol studies mentioned above, studies of thyroid hormone measurements 
and thyroid diseases can be categorized into: 1) general populations for which many have been 
cross-sectional (e.g., Melzer et al., 2010; Wang et al., 2013; Webster et al., 2016; Wen et al., 
2013); 2) the mid-Ohio river valley community (Knox et al., 2011; Lopez-Espinosa et al., 2012; 
Winquist and Steenland 2014b) and 3) occupational studies (Costa et al., 2009; Olsen and Zobel, 
2007; Sakr et al., 2007a; 2007b; Steenland et al. 2015). The studies of general populations did 
not yield consistent results with measured thyroid hormones and could be subject to reverse 
causation (Webster et al. 2016) as GFR will decrease in the untreated or subclinical hypothyroid 
state and increase in the untreated hyperthyroid or subclinical state, both of which can be 
normalized upon treatment (Dousdampanis et al., 2014; Koulouri et al., 2013; Woodward et al., 
2008).  Such an effect on GFR may retain or eliminate unbound PFOA, respectively. In the mid-
Ohio river valley studies, PFOA exposure was measured in cross-sectional studies (Knox et al. 
2011; Lopez-Espinosa et al., 2012) and estimated via exposure models in a longitudinal study of 
a community with diagnosed functional thyroid disease (Winquist and Steenland 2014b). The 
latter study reported associations for women diagnosed mainly with hyperthyroidism and for 
men with hypothyroidism. Occupational studies that have measured thyroid hormones did not 
report consistent associations with thyroid hormones nor did they provide workers’ thyroid 
disease histories, except for a prospective study (Steenland et al. 2015) that reported an exposure 
trend with PFOA for hypothyroidism in male workers.   
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4.3 PFOA and Liver Enzymes and Function 
During this six-week phase 1 trial, ALT and all other liver enzymes appeared unaffected by 
plasma concentrations of PFOA up to 1530 µM.  Nor did it appear hepatic functional changes 
were altered as analyzed by fibrinogen, PTT, and aPTT.  
In rats and mice treated with APFO, liver effects such as increased serum ALT and AST values 
(Butenhoff et al., 2012a; Minata et al., 2010; Son et al., 2008); peroxisome proliferation with 
subsequent hepatocellular hypertrophy (Elcombe et al., 2010; Haughom and Spydevold, 1992; 
Loveless et al., 2006;); and increased incidence of hepatocellular adenoma in rats (Biegel et al., 
2001; Butenhoff et al., 2012a) were reported, but these changes were attributed to PPARα 
activation, a mode of action unlikely to result in human liver tumors (Corton et al., 2014; Das et 
al. 2017). An increased liver weight reported in an APFO feeding study of monkeys was due, in 
part, to adaptive hepatocellular hypertrophy possibly as a result of mitochondrial proliferation 
(Butenhoff et al., 2002); no corroborative changes in either serum ALT or alkaline phosphatase 
occurred.  Studies of the mid-Ohio river valley community reported small shifts in liver enzymes 
with increasing PFOA (Darrow et al. 2016; Gallo et al., 2012).  The C8 Science Panel (2012b) 
considered this within normal physiologic ranges and found other study population results 
inconsistent; thus, they were uncertain whether PFOA was the cause of these modest liver 
enzyme associations but this did not reflect in any increased risk in liver disease, including 
medically validated enlarged liver, fatty liver, or cirrhosis.   
4.4 PFOA and Kidney Function  
Serum creatinine, urea, and uric acid were not associated with the PFOA concentrations in this 
phase 1 trial. Two-year bioassays in rats (Biegel et al., 2001; Butenhoff et al., 2012a) and a six-
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month study in monkeys (Butenhoff et al., 2002) did not find treatment-related renal effects with 
APFO. Epidemiologic cross-sectional studies have associated chronic kidney disease in children 
and adults with PFOA (Kataria et al., 2015; Shankar et al., 2011a;) or with hyperuricemia 
(Geiger et al. 2013; Shankar 2011b; Steenland et al., 2010); however, these findings were likely 
confounded by the GFR (Watkins et al., 2013; Dhingra et al., 2017). Dhingra et al. (2016) 
reported the mid-Ohio river valley population was not at an increased risk from chronic kidney 
disease based on their community worker longitudinal study of modeled cumulative serum 
PFOA concentrations. 
4.5 PK/PD Modeling 
Individual response is the result of a complex interaction of exposure and biology and it is very 
difficult to untangle the causal effects (via dependent clinical measures) of an exposure unless 
they are considered altogether systemically. The novelty of the PK/PD model is the information 
theoretic GSUA-driven model design and evaluation approach. This approach, incorporating 
stochastic parameters and state variables, optimizes the tradeoff between model complexity, 
uncertainty, and relevance. Non-linearity is assessed by considering all pdfs of model input 
factors and their interdependencies for multiple predicted patterns, interdependencies that are 
usually neglected. Optimization is achieved by minimizing three independent evaluation criteria 
(RMSE, KL, and AIC). This modeling approach addresses the uncertainty of data and extends 
the observed and discrete biological dynamics to a continuous domain. Hence, the model itself 
also evaluates the consistency and reliability of the data. Additionally, it helps to identify 
transition ranges and predict unobserved exposure dynamics 
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4.6 Study Limitations 
The main limitation of the study is that it used as subjects late-stage cancer patients whose 
metabolic activity may differ considerably from healthy individuals. Although there is no 
evidence that any of the cancers involved or treatments received prior to the study had systematic 
effects on the metabolic functions studied, it cannot be asserted with absolute confidence that no 
such systematic effects existed. 
The sample size and study length is limited, but the observation of impacts on two clinical 
chemistries (total cholesterol and fT4) suggests that this limitation is not absolute. It may be that 
other chemistries were affected, but the power of the study design was inadequate to detect the 
effects. Although subjects were not selected randomly for inclusion in dose groups, but were 
taken serially over time, this limitation leading to systematic bias by group would depend upon 
mechanisms not apparent to the investigators. In addition, changes over time within individuals 
are consistent with changes seen in the population averages and pdfs. 
Another limitation as it applies to the epidemiologic generalization of the results is that much 
lower serum concentrations as previously reported in workers, communities affected through 
PFOA-containing drinking water, and general populations, were not studied. Very low doses 
having opposite effects on cholesterol, such that increases in cholesterol are seen for PFOA 
concentrations that are orders of magnitude smaller than those doses administered to these cancer 
patients, is perhaps plausible. However, we have not uncovered research identifying such a 
mechanism in humans. 
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Conclusions  
Health concerns about the low levels of PFOA in the environment have been raised by 
observational studies. Using data from this phase 1 study of PFOA, we addressed the effects of 
exposure to a very wide range of PFOA, including extremely high PFOA concentrations. For 
levels of PFOA more than four orders of magnitude higher than the levels observed in general 
populations, there was no evidence of any major effects other than a decrease in total cholesterol 
(but not HDL) and an increase in fT4 (but not TSH) for increasing levels of PFOA plasma 
concentration. These non-linear effects that show changes into the probability distribution of 
cholesterol and fT4 are evidence for the importance of probabilistic versus linear models. Our 
findings are consistent with animal models and may contribute to focusing the evaluation of 
human health risks of PFOA in the environment, by motivating re-examination of the 
implications of population studies exposed to much lower levels of PFOA. These observational 
studies have reported contrary associations, but currently understood biology does not support 
the existence of such conflicting effects. 
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Table 1.  Treatment Data for the 49 Subjects in the Phase 1 Clinical Trial 
  APFO   Number of 
Dose (mg) Subjects 6 Weeks (wks) of Treatment (Yes/No)   
Initial single 
dose cohort 
50  3 (Single dose week 1 only)  _  _  
  
Repeat weekly  
dose cohorts  
50  1 Yes = 1;  No = 0  
100  3 Yes = 2; No = 1  (missed  wks 5 – 6) 
200  3 Yes = 3; No = 0 
  300  4 Yes = 2; No = 2 (1 missed  wk 6; 1 missed  wks 2 – 6 
450  3 Yes = 2; No = 1 (missed wk 6) 
600  7 Yes = 4; No = 3 (1 missed wk 5; 2 missed wks 4 – 6) 
750  3 Yes = 2; No = 1 (missed wk 6) 
950  4 Yes = 2; No = 2 (1 missed wk 6; 1 missed wks 2 – 6) 
1000  12 Yes = 7; No = 5  (1 missed wk 4; 1 missed wk 5; 
     1 missed wk 3 and wk 6; 2 missed wks 4 – 6) 
1200  6 Yes = 2; No = 4 (1 missed wk 4; 1 missed wks 5 – 6; 
     2 missed wk 6)       
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Figure Legends  
 
Figure 1. Conceptual diagram of the PK/PD compartmental model. The black and red boxes refer 
to the stochastic pharmacokinetic (PK) and pharmacodynamics (PD) model, respectively. Dose 
of the drug, plasma concentration, unbound concentration in the tissue and effect in the 
biological compartments are the quantities that are calculated by the model. Cpu and C2 
represent unbound concentration in the plasma compartment and in a second tissue compartment. 
The parameters V, ka, k12, k21, and k10 are calibrated simultaneously in a fitting model that 
considers the data and aim to maximize prediction accuracy. The concentration in the effect 
compartment was linked to the plasma compartment by a first-order equilibrium rate constant ke. 
Ceu denotes the unbound effect compartment concentration. E denotes the effect variable, and a 
and b (see Equation 4) are calibrated input factors whose specific value depends on the effect 
compartment (or clinical biomarker) but their probability distribution does not. i and j refer to 
any clinical biomarker that are mutually dependent.  
Figure 2. Observed and predicted plasma concentration of PFOA over time conditional on the 
assigned dose. Predictions and data are solid and dashed lines as a function of dose category. The 
PK/PD model predictions are shown only for the lowest and highest dose category. Variability 
around PK curves is a function of the pdf assigned to the input factors and numerical Monte 
Carlo variability related to the Sobol sampling scheme.  
 
Figure 3.  GEE analysis of cholesterol and PFOA.  Slope and 95% CI presented. 
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Figure 4. Observed and predicted probability distribution function of cholesterol and dependent 
on PFOA concentration. (Left) The solid pdfs are cholesterol levels for the lowest and highest 
PFOA concentration categories predicted by repeated runs of the PK/PD model while the dashed 
pdf are from smoothed observations. (Right) Box plots and slope of the observed and slope of 
the model-predicted average value of cholesterol plotted as a function of each of the 10 PFOA 
serum concentration categories. The black and red bars in the boxes represent the median and the 
mean value respectively. Dots above boxes are outliers (upper dots are more than 3/2 times of 
upper quartile, while lower dots are less than 3/2 times of lower quartile). The extremes of the 
whiskers are the maximum and minimum values for each category excluding outliers. The 
extremes of the boxes are the third and first quartiles.  
Figure 5. Probability distribution functions of total cholesterol over increasing PFOA 
concentrations for all subjects in the cohort. The colors of the pdf correspond to the PFOA 
concentrations groups as in the legend.  
Figure 6. Observed probability distribution function of cholesterol. Total cholesterol, HDL, and 
LDL are considered. HDL is invariant for any PFOA class, and by LDL that is decreasing for 
increasing values of PFOA. The pdfs of cholesterol for the lowest and highest PFOA plasma 
classes are shown with a thick line to emphasize the change in their probabilistic structure. 
Figure 7.  GEE analysis of fT4 and PFOA.  Slope and 95% CI presented  
 
Figure 8. Observed and predicted probability distribution function of fT4 and dependent on 
PFOA concentration. (Left) The solid pdfs are fT4 levels for the lowest and highest PFOA 
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concentration categories predicted by repeated runs of the PK/PD model while the dashed pdf are 
from smoothed observations. (Right) Box plots and slope of the observed and slope of the 
model-predicted average value of fT4 plotted as a function of each of the 10 PFOA serum 
concentration categories. The black and red bars in the boxes represent the median and the mean 
value respectively. Dots above boxes are outliers (upper dots are more than 3/2 times of upper 
quartile, while lower dots are less than 3/2 times of lower quartile). The extremes of the whiskers 
are the maximum and minimum values for each category excluding outliers. The extremes of the 
boxes are the third and first quartiles. 
Figure 9. Observed probability distribution function of thyroid function. TSH is invariant and 
fT4 is higher for higher values of PFOA. The pdfs of fT4 for the lowest and highest PFOA 
plasma classes are shown with a thick line to emphasize the change in their probabilistic 
structure. 
Figure 10. Observed probability distribution function of ALT. ALT is invariant for any PFOA 
categorization.  
Figure 11. Observed probability distribution function of serum creatinine. Serum creatinine 
appears to be slightly increasing for increasing values of PFOA but this was based on one 
individual.  
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Figure 1. Conceptual diagram of the PK/PD compartmental model. The black and red boxes refer to the 
stochastic pharmacokinetic (PK) and pharmacodynamics (PD) model, respectively. Dose of the drug, plasma 
concentration, unbound concentration in the tissue and effect in the biological compartments are the 
quantities that are calculated by the model. Cpu and C2 represent unbound concentration in the plasma 
compartment and in a second tissue compartment. The parameters V, ka, k12, k21, and k10 are calibrated 
simultaneously in a fitting model that considers the data and aim to maximize prediction accuracy. The 
concentration in the effect compartment was linked to the plasma compartment by a first-order equilibrium 
rate constant ke. Ceu denotes the unbound effect compartment concentration. E denotes the effect variable, 
and a and b (see Equation 4) are calibrated input factors whose specific value depends on the effect 
compartment (or clinical biomarker) but their probability distribution does not. i and j refer to any clinical 
biomarker that are mutually dependent.  
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Figure 2. Observed and predicted plasma concentration of PFOA over time conditional on the assigned dose. 
Predictions and data are solid and dashed lines as a function of dose category. The PK/PD model predictions 
are shown only for the lowest and highest dose category. Variability around PK curves is a function of the 
pdf assigned to the input factors and numerical Monte Carlo variability related to the Sobol sampling 
scheme.  
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Figure 3. GEE analysis of cholesterol and PFOA.  Slope and 95% CI presented.  
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Figure 4. Observed and predicted probability distribution function of cholesterol and dependent on PFOA 
concentration. (Left) The solid pdfs are cholesterol levels for the lowest and highest PFOA concentration 
categories predicted by repeated runs of the PK/PD model while the dashed pdf are from smoothed 
observations. (Right) Box plots and slope of the observed and slope of the model-predicted average value of 
cholesterol plotted as a function of each of the 10 PFOA serum concentration categories. The black and red 
bars in the boxes represent the median and the mean value respectively. Dots above boxes are outliers 
(upper dots are more than 3/2 times of upper quartile, while lower dots are less than 3/2 times of lower 
quartile). The extremes of the whiskers are the maximum and minimum values for each category excluding 
outliers. The extremes of the boxes are the third and first quartiles.  
 
177x55mm (300 x 300 DPI)  
 
 
Downloaded from https://academic.oup.com/toxsci/advance-article-abstract/doi/10.1093/toxsci/kfy035/4865972
by Library - Duncan of Jordanstone user
on 08 March 2018
  
 
 
Figure 5. Probability distribution functions of total cholesterol over increasing PFOA concentrations for all 
subjects in the cohort. The colors of the pdf correspond to the PFOA concentrations groups as in the legend. 
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Figure 6. Observed probability distribution function of cholesterol. Total cholesterol, HDL, and LDL are 
considered. HDL is invariant for any PFOA class, and by LDL that is decreasing for increasing values of PFOA. 
The pdfs of cholesterol for the lowest and highest PFOA plasma classes are shown with a thick line to 
emphasize the change in their probabilistic structure.  
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Figure 7. GEE analysis of fT4 and PFOA.  Slope and 95% CI presented  
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Figure 8. Observed and predicted probability distribution function of fT4 and dependent on PFOA 
concentration. (Left) The solid pdfs are fT4 levels for the lowest and highest PFOA concentration categories 
predicted by repeated runs of the PK/PD model while the dashed pdf are from smoothed observations. 
(Right) Box plots and slope of the observed and slope of the model-predicted average value of fT4 plotted as 
a function of each of the 10 PFOA serum concentration categories. The black and red bars in the boxes 
represent the median and the mean value respectively. Dots above boxes are outliers (upper dots are more 
than 3/2 times of upper quartile, while lower dots are less than 3/2 times of lower quartile). The extremes of 
the whiskers are the maximum and minimum values for each category excluding outliers. The extremes of 
the boxes are the third and first quartiles.  
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Figure 9. Observed probability distribution function of thyroid function. TSH is invariant and fT4 is higher for 
higher values of PFOA. The pdfs of fT4 for the lowest and highest PFOA plasma classes are shown with a 
thick line to emphasize the change in their probabilistic structure.  
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Figure 10. Observed probability distribution function of ALT. ALT is invariant for any PFOA categorization.  
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Figure 11. Observed probability distribution function of serum creatinine. Serum creatinine appears to be 
slightly increasing for increasing values of PFOA but this was based on one individual.  
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